Open AccessClinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma
Author(s) -
Mohamed Saleh Ismail,
Manal M. Hassan,
Saira Khaderi,
Wael Ahmed Yousry,
Maha Mohsen Kamal El-Din,
Mohamed Mohamed Bahaa El-Din,
Osama Aboelfotoh El Sayed,
Ahmed O. Kaseb,
John A. Goss,
Fasiha Kanwal,
Prasun K. Jalal
Publication year - 2020
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v12.i9.628
Subject(s) - medicine , hepatocellular carcinoma , hepatitis c virus , gastroenterology , liver transplantation , odds ratio , transplantation , viremia , hepatitis c , oncology , immunology , virus
Recurrent hepatitis C virus (HCV) infection of transplanted liver allografts is universal in patients with detectable HCV viremia at the time of transplantation. Direct-acting antiviral (DAA) therapy has been adopted as the standard of care for recurrent HCV infection in the post-transplant setting. However, there are insufficient data regarding its efficacy in liver transplant (LT) recipients with a history of hepatocellular carcinoma (HCC), and the risk of HCC recurrence after DAA therapy is unknown.